BIO National Venture Conference 2009 takes place March 31 – April 1, 2009 at the Sheraton Boston Hotel in Boston.
Business Wire is the official news wire for BIO National Venture Conference 2009. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.
Listed below are the BIO National Venture Conference 2009 presenter profiles.
| Company: | Catena Pharmaceuticals, Inc. |
| Investor Relations Contact: | Ian Mehr |
| Investor Relations Contact Phone: | 888-265-1353 |
| Web: | www.catenapharma.com |
| Date of Presentation: | April 1, 2009, 2:25 PM |
| While therapeutic advances have been made, cancer remains a scourge as the second leading cause of death in the United States, creating intense suffering and major economic costs on the healthcare system. Catena Pharmaceuticals's proprietary technology has demonstrated a unique ability to aggressively fight the growth of cancerous tumors in animal models. Catena's exciting drug platform attacks cancer through a validated drug target class and by a proven mechanism: blocking blood flow to tumors (angiogenesis) and starving them of oxygen. Catena seeks financing to advance its lead anti-cancer drug candidate, VPC51299, towards human clinical trials. | |
| Company: | GliaMed, Inc. |
| Investor Relations Contact: | Andrew Uprichard, CEO |
| Investor Relations Contact Phone: | 1 (508) 626-0077 x112 |
| Web: | www.GliaMed.com |
| Date of Presentation: | 3/31/09 |
| GliaMed is developing a small molecule approach to stem cell therapy. Founded in 2001, the company is developing Regenerative Immunophilin Ligands (RILs). In preclinical models, RILs have been shown to induce the localized expression of transcription factors characteristic of pluripotent stem cells at the site of acute disease or trauma. These cells can then be reprogrammed by local signals to become neurons, cardiac myocytes, chondrocytes or other cell types, which then contribute to fully differentiated tissues such as skin. GliaMed's lead candidate, GM1485, has been administered to more than 500 human subjects. The company acquired this compound in 2007. | |
| Company: | Mirna Therapeutics |
| Investor Relations Contact: | Rollie Carlson |
| Investor Relations Contact Phone: | 512-681-5211 |
| Web: | http://www.mirnarx.com/ |
| Date of Presentation: | 4/1/09 |
| Mirna Therapeutics, Inc. ("Mirna") is a biopharmaceutical company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to be a major "platform" company in the emerging field of miRNA-based therapeutics. Mirna has developed two miRNA drug candidates that are able to inhibit tumor development and metastasis in multiple mouse models of prostate and lung cancer. Mirna is a spin-off of Asuragen, a miRNA-based diagnostics company. Mirna was founded on miRNA technologies and intellectual property first developed at Ambion, Inc. that date back to 2002. | |
| Company: | NeurAxon |
| Investor Relations Contact: | Chris Erdman |
| Investor Relations Contact Phone: | 781-235-3060 |
| Web: | www.neuraxon.com |
| Date of Presentation: | April 1, 2009 10:35-10:50am |
| NeurAxon is a leader in discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon has generated a proprietary pipeline of five product candidates for the following indications: acute migraine, neuropathic pain, rheumatoid arthritis, migraine prophylaxis and severe pain. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT (5-HT is the mechanism of action of triptans, the largest class of migraine drugs) agonism that is being developed for the treatment of acute migraine. | |
About Business Wire
Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.
Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.
Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.
Business Wire
Global Event Services
310-820-9473
http://www.businesswire.com
http://www.tradeshownews.com
